SALT LAKE CITY, Dec. 12, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the myRisk Hereditary Cancer test found 51 percent more patients with a higher risk of hereditary breast and ovarian cancer than did testing for the BRCA1 and BRCA2 genes alone. myRisk is a new diagnostic test that uses next-generation sequencing technology to evaluate 25 genes associated with eight major hereditary cancers including: breast, colorectal, ovarian, endometrial, pancreatic, prostate, gastric and melanoma.
Help employers find you! Check out all the jobs and post your resume.
